Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective

Health Economics Review

Table 4 Drug treatment, drug-related adverse event and metastasis cost items: clinical practice, unit costs and total cost

Drug treatments cost item		Prescription (%)
		SCLC		NSCLC
Chemotherapeutics
Adjuvant-Neoadjuvant		–		20
Advanced first-line therapy		100		74
Poor performance		25		25
Advanced second-line therapy		45		20
Advanced third-line therapy		10		10
Other drugs		SCLC	NSCLC	Total (€)
Analgesics		85	85	243.74
Steroids		45	45	11.16
Bisphosphonates		20	20	648.96
Nutrition (3-month)		100	100	320.07
G-CSF		2.5	2.5	841.94
Per patient drug treatment cost (€)		SCLC		1,484.19
		NSCLC		2,765.58
Adverse events cost item		Annual rate (%)		Unit cost (€)	Total (€)
		SCLC	NSCLC
Rash		2	2	90.5	1.81
Febrile Neutropenia		4	4	5,019.9	200.79
Anemia		50	50	144.3	72.16
Nausea/Vomiting		100	100	77.6	77.60
Diarrhea		15	15	29.99	5.40
Constipation		70	70	18.4	12.89
Pulmonary Toxicity		25	25	635.51	133.87
Fatigue		75	75	194.16	145.62
Hypoalbuminemia		10	10	281.67	28.16
Neutropenia		6	6	983.77	59
Deep Vein Thrombosis		10	10	586.19	58.62
Infection		50	50	11.75	5.9
Anorexia		50	50	364.5	182.23
Thrombocytopenia		5	5	162.34	8
Edema		10	10	26	2.60
Per patient drug-related adverse event cost (€)					999.57
Metastasis cost item		Annual rate (%)		Unit cost (€)	Total (€)
		SCLC	NSCLC
Central Nervous System	diagnosis	23	23	1,811.06	93.72
	follow up	40	40	1,811.06	93.72
Bone		32.5	32.5	1,253.87	407.51
Liver		12.5	12.5	4,058.71	507.34
Pleura		14.3	14.3	102.02	14.59
Kidney		15	15	1,252.42	21.29
Per patient metastasis cost (€)					1,516.40

ISSN: 2191-1991